Immunotoxins: The Role of the Toxin
Reads0
Chats0
TLDR
The utility of protein toxins, of both bacterial and plant origin, joined to antibodies for targeting cancer cells are discussed, both for treating human disease and probes of cellular function.Abstract:
Immunotoxins are antibody-toxin bifunctional molecules that rely on intracellular toxin action to kill target cells. Target specificity is determined via the binding attributes of the chosen antibody. Mostly, but not exclusively, immunotoxins are purpose-built to kill cancer cells as part of novel treatment approaches. Other applications for immunotoxins include immune regulation and the treatment of viral or parasitic diseases. Here we discuss the utility of protein toxins, of both bacterial and plant origin, joined to antibodies for targeting cancer cells. Finally, while clinical goals are focused on the development of novel cancer treatments, much has been learned about toxin action and intracellular pathways. Thus toxins are considered both medicines for treating human disease and probes of cellular function.read more
Citations
More filters
Journal ArticleDOI
Advances in Anticancer Immunotoxin Therapy
TL;DR: A novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies that consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing.
Journal ArticleDOI
Photonanomedicine: a convergence of photodynamic therapy and nanotechnology
Girgis Obaid,Mans Broekgaarden,Anne-Laure Bulin,Huang-Chiao Huang,Jerrin Kuriakose,Joyce F. Liu,Tayyaba Hasan,Tayyaba Hasan +7 more
TL;DR: The encouraging investigations that emphasize the potent synergy between photochemistry and nanotherapeutics, in addition to the growing realization of the value of these multi-faceted theranostic nanoplatforms, will assist in driving PNM formulations into mainstream oncological clinical practice as a necessary tool in the medical armamentarium.
Journal ArticleDOI
Immunotoxins for leukemia
TL;DR: Recombinant immunotoxins have been shown to be highly cytotoxic to leukemic blasts in vitro, in xenograft model systems, and in early-phase clinical trials in humans, and will likely play an increasing role in the treatment of leukemia.
Journal ArticleDOI
Peptide ligand-mediated targeted drug delivery of nanomedicines
TL;DR: Peptide ligands are advantageous over other classes of targeting ligands due to their accessibility of high-throughput screening, ease of synthesis, high specificity and affinity, etc.
Journal ArticleDOI
Immunotoxin: A new tool for cancer therapy.
TL;DR: Current trends and researches are ongoing on finding proteins that in combination with immunotoxins have minimal immunogenicity and the most potency for target cell killing.
References
More filters
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Journal ArticleDOI
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
James S. Huston,D. Levinson,Meredith Mudgett-Hunter,M S Tai,Jirí Novotný,Michael N. Margolies,R J Ridge,Robert E. Bruccoleri,Edgar Haber,R Crea +9 more
TL;DR: A biosynthetic antibody binding site, which incorporated the variable domains of anti-digoxin monoclonal antibody 26-10 in a single polypeptide chain, was produced in Escherichia coli by protein engineering.
Journal ArticleDOI
Single-chain antigen-binding proteins
Robert E. Bird,Karl D. Hardman,James W. Jacobson,Syd Johnson,Bennett M. Kaufman,Shwu Maan Lee,Timothy K. Lee,Sharon H. Pope,Gary S. Riordan,Marc Whitlow +9 more
TL;DR: Three single-chain antigen-binding proteins are novel recombinant polypeptides, composed of an antibody variable light-chain amino acid sequence tethered to a variable heavy-chain sequence (VH) by a designed peptide that links the carboxyl terminus of the VL sequence to the amino terminusof the VH sequence.
Journal ArticleDOI
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion
G. Köhler,C. Milstein +1 more
TL;DR: Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody‐producing cells that are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice.
Journal ArticleDOI
One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell.
TL;DR: Erythrocyte ghosts containing a known number of molecules of purified fragment A of diphtheria toxin with a constant amount of FITC-BSA as a fluorescence marker demonstrated that a single molecule of fragment A was sufficient to kill a cell.
Related Papers (5)
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
John E. Weldon,Ira Pastan +1 more